In reply: We thank Meyer and colleagues for their interest in our article. The risk of sodium–glucose cotransporter type 2 (SGLT2) inhibitor‐associated diabetic ketoacidosis in acutely unwell patients and people using ketogenic diets is already outlined in our article and does not require further comment.1
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- 1. Hamblin PS, Wong R, Bach LA. Sodium–glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis. Med J Aust 2020; 212: 294–296. https://www.mja.com.au/journal/2020/212/7/sodium-glucose-cotransporter-type-2-inhibitors-managing-small-critical-risk
- 2. Hamblin PS, Wong R, Ekinci EI, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab 2019; 104: 3077–3087.
- 3. Australian Diabetes Society. Alert update: periprocedural diabetic ketoacidosis (DKA) with SGLT2 inhibitor use. January 2020. http://diabetessociety.com.au/documents/ADS_DKA_SGLT2i_Alert_update_2020.pdf (viewed Nov 2020).
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.